These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 10189480

  • 1. Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling.
    Sugawara Y, Zasadny KR, Grossman HB, Francis IR, Clarke MF, Wahl RL.
    Radiology; 1999 Apr; 211(1):249-56. PubMed ID: 10189480
    [Abstract] [Full Text] [Related]

  • 2. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours.
    Spermon JR, De Geus-Oei LF, Kiemeney LA, Witjes JA, Oyen WJ.
    BJU Int; 2002 Apr; 89(6):549-56. PubMed ID: 11942962
    [Abstract] [Full Text] [Related]

  • 3. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma.
    Kollmannsberger C, Oechsle K, Dohmen BM, Pfannenberg A, Bares R, Claussen CD, Kanz L, Bokemeyer C.
    Cancer; 2002 May 01; 94(9):2353-62. PubMed ID: 12015760
    [Abstract] [Full Text] [Related]

  • 4. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients.
    Stephens AW, Gonin R, Hutchins GD, Einhorn LH.
    J Clin Oncol; 1996 May 01; 14(5):1637-41. PubMed ID: 8622082
    [Abstract] [Full Text] [Related]

  • 5. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse.
    Hain SF, O'Doherty MJ, Timothy AR, Leslie MD, Harper PG, Huddart RA.
    Br J Cancer; 2000 Oct 01; 83(7):863-9. PubMed ID: 10970686
    [Abstract] [Full Text] [Related]

  • 6. FDG PET for detection and therapy control of metastatic germ cell tumor.
    Cremerius U, Effert PJ, Adam G, Sabri O, Zimmy M, Wagenknecht G, Jakse G, Buell U.
    J Nucl Med; 1998 May 01; 39(5):815-22. PubMed ID: 9591582
    [Abstract] [Full Text] [Related]

  • 7. Untreated primary lung and breast cancers: correlation between F-18 FDG kinetic rate constants and findings of in vitro studies.
    Torizuka T, Zasadny KR, Recker B, Wahl RL.
    Radiology; 1998 Jun 01; 207(3):767-74. PubMed ID: 9609902
    [Abstract] [Full Text] [Related]

  • 8. The role of positron emission tomography in germ cell cancer.
    De Santis M, Pont J.
    World J Urol; 2004 Apr 01; 22(1):41-6. PubMed ID: 15024601
    [Abstract] [Full Text] [Related]

  • 9. Can nitrogen-13 ammonia kinetic modeling define myocardial viability independent of fluorine-18 fluorodeoxyglucose?
    Beanlands RS, deKemp R, Scheffel A, Nahmias C, Garnett ES, Coates G, Johansen HL, Fallen E.
    J Am Coll Cardiol; 1997 Mar 01; 29(3):537-43. PubMed ID: 9060890
    [Abstract] [Full Text] [Related]

  • 10. The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors--prospects for management.
    Pfannenberg AC, Oechsle K, Bokemeyer C, Kollmannsberger C, Dohmen BM, Bares R, Hartmann JT, Vonthein R, Claussen CD.
    World J Urol; 2004 Jun 01; 22(2):132-9. PubMed ID: 14735310
    [Abstract] [Full Text] [Related]

  • 11. Regional kinetic constants and cerebral metabolic rate for glucose in normal human volunteers determined by dynamic positron emission tomography of [18F]-2-fluoro-2-deoxy-D-glucose.
    Heiss WD, Pawlik G, Herholz K, Wagner R, Göldner H, Wienhard K.
    J Cereb Blood Flow Metab; 1984 Jun 01; 4(2):212-23. PubMed ID: 6609929
    [Abstract] [Full Text] [Related]

  • 12. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading.
    Dimitrakopoulou-Strauss A, Strauss LG, Schwarzbach M, Burger C, Heichel T, Willeke F, Mechtersheimer G, Lehnert T.
    J Nucl Med; 2001 May 01; 42(5):713-20. PubMed ID: 11337565
    [Abstract] [Full Text] [Related]

  • 13. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer.
    Minn H, Lapela M, Klemi PJ, Grénman R, Leskinen S, Lindholm P, Bergman J, Eronen E, Haaparanta M, Joensuu H.
    J Nucl Med; 1997 Dec 01; 38(12):1907-11. PubMed ID: 9430467
    [Abstract] [Full Text] [Related]

  • 14. 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy.
    Johns Putra L, Lawrentschuk N, Ballok Z, Hannah A, Poon A, Tauro A, Davis ID, Hicks RJ, Bolton DM, Scott AM.
    Urology; 2004 Dec 01; 64(6):1202-7. PubMed ID: 15596197
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of the effect of glucose ingestion and kinetic model configurations of FDG in the normal liver.
    Choi Y, Hawkins RA, Huang SC, Brunken RC, Hoh CK, Messa C, Nitzsche EU, Phelps ME, Schelbert HR.
    J Nucl Med; 1994 May 01; 35(5):818-23. PubMed ID: 8176464
    [Abstract] [Full Text] [Related]

  • 16. FDG-PET evaluation of retroperitoneal metastases of testicular cancer before and after chemotherapy.
    Reinhardt MJ, Müller-Mattheis VG, Gerharz CD, Vosberg HR, Ackermann R, Müller-Gärtner HW.
    J Nucl Med; 1997 Jan 01; 38(1):99-101. PubMed ID: 8998160
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.